Learning from low income countries: Poor patients deserve more science and less advocacy

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7489.479 (Published 24 February 2005) Cite this as: BMJ 2005;330:479
  1. Carol C Adelman (carola@hudsondc.org), director,
  2. Jeremiah Norris, senior fellow
  1. Center for Science in Policy, Hudson Institute, 1015 18th Street NW, Suite 300, Washington, DC 20036, USA

    EDITOR—Hogerzeil, who works for the World Health Organization in Geneva, contends that WHO selects essential medicines within a therapeutic class on the basis of comparative efficacy, safety, and cost.1 His reference text, Essential Medicines,2 is at variance with that contention.

    WHO's choice to treat 3 million by 2005 is triple dose combination antiretroviral treatment from India. In the April listing, WHO says: “The Committee …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription